Bispecific Anti-Mouse PD-1 / VEGF-A In Vivo Antibody

Mouse

PD-1 + VEGF-A

>1mg/ml

Mouse IgG2c LALAPG Kappa

Mouse

ICH1132, ICH1278

ICH3002

Q02242;Q00731

Blue ice

Combining checkpoint blockade with anti-angiogenic activity is a leading dual strategy in tumour immunology, and a fully murine surrogate enables clean syngeneic modelling. This bispecific antibody simultaneously engages mouse PD-1 and VEGF-A, built from the anti-PD-1 clone RMP1-14 and the anti-VEGF clone B20-4.1.1 on a mouse IgG2c LALA-PG kappa backbone whose effector function is silenced. Validated for in vivo use, it lets researchers interrogate combined PD-1 and VEGF-A blockade in mouse models. Supplied in a low-endotoxin format suitable for in vivo use and manufactured in scalable milligram (mg) to gram (g) quantities, this research-use-only reagent serves high-throughput and bulk preclinical immuno-oncology studies.

RMP1-14 / B20-4.1.1

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

0.2 μM filtered solution of 1x PBS.

This antibody is stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

In vivo

Products are for research use only. Not for use in diagnostic or therapeutic procedures.